Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Hohlfeld

Showing results (21-30 of 203) with videos related to

Pageof 21
Sort By:
Annals of Neurology|September 29, 2021
CD20<sup>+</sup> T Cells as Pathogenic Players and Therapeutic Targets in MSEdgar Meinl, Reinhard Hohlfeld
MMW Fortschritte Der Medizin|April 29, 2006
[Suspected multiple sclerosis]Hannah Pellkofer, Reinhard Hohlfeld
Nature Clinical Practice. Neurology|August 26, 2006
Drug insight: using monoclonal antibodies to treat multiple sclerosisReinhard Hohlfeld, Hartmut Wekerle
The Lancet. Neurology|August 30, 2016
Antiglutamatergic therapy for multiple sclerosis?Reinhard Hohlfeld, Martin Kerschensteiner
Neurology|March 2, 2011
Modulation of sphingosine 1-phosphate signaling in neurologic diseaseJack Antel, Reinhard Hohlfeld
Neurology|January 13, 2012
What T-cell receptors can tell us about neurologic diseaseReinhard Hohlfeld, Klaus Dornmair
International MS Journal|January 20, 2006
MS treatment optimization: report from the 21st ETRIMS/10th ACTRIMS Congress, 28 September-1 October 2005, Thessaloniki, GreeceMichel Clanet, Reinhard Hohlfeld
Seminars in Immunopathology|December 4, 2009
Progress in understanding inflammatory and autoimmune diseases of the central nervous systemReinhard Hohlfeld, Ludwig Kappos
Neurology|March 18, 2009
Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successesHeinz Wiendl, Reinhard Hohlfeld
Neurology|September 20, 2013
A bird's-eye view of T cells during natalizumab therapyReinhard Hohlfeld, Olaf Stüve
Pageof 21

Showing results (21-30 of 203) with videos related to

Sort By:
Pageof 21
Annals of Neurology|September 29, 2021
CD20<sup>+</sup> T Cells as Pathogenic Players and Therapeutic Targets in MSEdgar Meinl, Reinhard Hohlfeld
MMW Fortschritte Der Medizin|April 29, 2006
[Suspected multiple sclerosis]Hannah Pellkofer, Reinhard Hohlfeld
Nature Clinical Practice. Neurology|August 26, 2006
Drug insight: using monoclonal antibodies to treat multiple sclerosisReinhard Hohlfeld, Hartmut Wekerle
The Lancet. Neurology|August 30, 2016
Antiglutamatergic therapy for multiple sclerosis?Reinhard Hohlfeld, Martin Kerschensteiner
Neurology|March 2, 2011
Modulation of sphingosine 1-phosphate signaling in neurologic diseaseJack Antel, Reinhard Hohlfeld
Neurology|January 13, 2012
What T-cell receptors can tell us about neurologic diseaseReinhard Hohlfeld, Klaus Dornmair
International MS Journal|January 20, 2006
MS treatment optimization: report from the 21st ETRIMS/10th ACTRIMS Congress, 28 September-1 October 2005, Thessaloniki, GreeceMichel Clanet, Reinhard Hohlfeld
Seminars in Immunopathology|December 4, 2009
Progress in understanding inflammatory and autoimmune diseases of the central nervous systemReinhard Hohlfeld, Ludwig Kappos
Neurology|March 18, 2009
Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successesHeinz Wiendl, Reinhard Hohlfeld
Neurology|September 20, 2013
A bird's-eye view of T cells during natalizumab therapyReinhard Hohlfeld, Olaf Stüve
Pageof 21